Key result
This editorial highlights key heart failure research, including a CRT risk score developed in 3629 patients, prognostic markers in HFpEF, and the COMMANDER-HF trial design.
Answers are grounded in this paper and cite their sources.
This editorial summarizes key heart failure research published in the July 2015 issue, including studies on acute HF, HFpEF, HFrEF, CRT risk stratification, and novel trial designs.
Mebazaa et al. review the use of agents with vasodilator properties for the treatment of acute HF.1 Better trials' design with early randomization, proper patients' selection, adequate endpoints, in addition to specific drugs' characteristics, will hopefully contribute to the identification of new drugs effective for the treatment of acute HF.1 Worsening HF is associated with higher risk for rehospitalizations and deaths in acute HF trials.2 Mentz et al. have confirmed its prognostic value and have found that this was not influenced by the time of occurrence and the intensity of treatment in 1,879 patients enrolled in the PROTECT trial.3 Uncertainties and dilemmas regarding HFpEF are reviewed by Ferrari et al.4 Echocardiographic predictors of clinical outcomes are analyzed in 538 HFpEF patients enrolled in the KaRen study with only E/e' as an independent predictor of deaths or HF hospitalizations after adjustment for baseline variables.5 Both abnormal QRS morphology and prolonged QRS duration were independent predictors of poorer outcomes in 2275 patients with HFrEF and mild symptoms enrolled in the EMPHASIS-HF trial.6 A simple risk stratification score after cardiac resynchronization therapy, based on age, gender, LVEF, NYHA class, atrial fibrillation, atrio-ventricular junction ablation, coronary heart disease, diabetes and ICD back-up has been developed in 3629 consecutive patients and validated in a cohort of 1524 other patients enrolled from 72 European centers.7 The advantages and limitations of this model are outlined in a comment by Normand and Dickstein.8 The hypothesis that the administration of the novel oral anticoagulant rivaroxaban may decrease events rate in patients with HFrEF is currently tested in the COMMANDER-HF trial, a randomised, double-blind, event-driven, multicentre study comparing oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with HFrEF, following an episode of HF decompensation:9 The rationale for this trial is outlined in an accompanying editorial.10 Lastly, the use of Wii gaming to improve exercise capacity and quality of life is discussed and will be formally tested in a new trial whose design is shown in our journal:11
No takes yet. Share an insight, caveat, or question.
Marco Metra (2015) conducted an editorial in Heart failure. This editorial highlights key heart failure research, including a CRT risk score developed in 3629 patients, prognostic markers in HFpEF, and the COMMANDER-HF trial design.
Synapse has enriched 10 related papers. Consider them for comparative context: